Atara Biotherapeutics Inc. (NASDAQ: ATRA) stock closed at 2.87 per share at the end of the most recent trading day (a 0.35% change compared to the prior day closing price) with a volume of 1.68M shares and market capitalization of 275.31M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 429 people. Atara Biotherapeutics Inc. CEO is Pascal Touchon.

The one-year performance of Atara Biotherapeutics Inc. stock is -70.27%, while year-to-date (YTD) performance is -12.5%. ATRA stock has a five-year performance of -92.76%. Its 52-week range is between 2.66 and 10.01, which gives ATRA stock a 52-week price range ratio of 2.86%

Atara Biotherapeutics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 1.77, a price-to-sale (PS) ratio of 5.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -65.93%, a ROC of -84.78% and a ROE of -109.85%. The company’s profit margin is -%, its EBITDA margin is -411.10%, and its revenue ttm is $63.35 Million , which makes it $0.67 revenue per share.

Of the last four earnings reports from Atara Biotherapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.40 for the next earnings report. Atara Biotherapeutics Inc.’s next earnings report date is 04th May 2023.

The consensus rating of Wall Street analysts for Atara Biotherapeutics Inc. is Moderate Buy (2.5), with a target price of $19.44, which is +577.35% compared to the current price. The earnings rating for Atara Biotherapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atara Biotherapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atara Biotherapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 8.90, ATR14 : 0.25, CCI20 : -87.21, Chaikin Money Flow : -0.05, MACD : -0.34, Money Flow Index : 31.11, ROC : -12.50, RSI : 32.16, STOCH (14,3) : 25.30, STOCH RSI : 0.12, UO : 50.33, Williams %R : -74.70), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atara Biotherapeutics Inc. in the last 12-months were: Amar Murugan (Sold 10 874 shares of value $49 713 ), Jakob Dupont (Sold 13 071 shares of value $59 760 ), Pascal Touchon (Sold 58 618 shares of value $307 761 ), Utpal Koppikar (Sold 26 731 shares of value $131 024 )